9 research outputs found
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
Background. Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant.Methods. We conducted a multicenter test-negative case-control study in patients aged â„16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, when the Delta variant was dominant (â„90% of SARS-CoV-2 infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16â64 years was also assessed.Results. We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving 2 doses â„14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8%â93.9%) among patients aged 16â64 years and 90.3% (95% CI, 73.6%â96.4%) among patients aged â„65 years. Among patients aged 16â64 years, vaccine effectiveness was 91.8% (95% CI, 80.3%â96.6%) within 1â3 months after full vaccination, and 86.4% (95% CI, 56.9%â95.7%) within 4â6 months.Conclusions. mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during JulyâSeptember 2021, when the Delta variant was dominant nationwide
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
Background: Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan. Methods: We conducted a multicenter test-negative case-control study. The study comprised indivi-duals aged â„16 visiting medical facilities with COVID-19-related signs or symptoms from 1 January to 26 June 2022, when Omicron BA.1 and BA.2 were dominant nationwide. We evaluated VE of primary and booster vaccination against symptomatic SARS-CoV-2 infections and relative VE of booster compared with primary.Results: We enrolled 7,931 episodes, including 3,055 test positive. The median age was 39, 48.0% were male, and 20.5% had underlying medical conditions. In individuals aged 16 to 64, VE of primary vaccination within 90 days was 35.6% (95% CI, 19.0â48.8%). After booster, VE increased to 68.7% (60.6â75.1%). In individuals aged â„65, VE of primary and booster was 31.2% (â44.0â67.1%) and 76.5% (46.7â89.7%), respectively. Relative VE of booster compared with primary vaccination was 52.9% (41.0â 62.5%) in individuals aged 16 to 64 and 65.9% (35.7â81.9%) in individuals aged â„65.Conclusions: During BA.1 and BA.2 epidemic in Japan, mRNA COVID-19 primary vaccination provided modest protection. Booster vaccination was necessary to protect against symptomatic infections
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
Background Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan. Methods We conducted a multicenter test-negative case-control study. The study comprised individuals aged â„16 visiting medical facilities with COVID-19-related signs or symptoms from 1 January to 26 June 2022, when Omicron BA.1 and BA.2 were dominant nationwide. We evaluated VE of primary and booster vaccination against symptomatic SARS-CoV-2 infections and relative VE of booster compared with primary. Results We enrolled 7,931 episodes, including 3,055 test positive. The median age was 39, 48.0% were male, and 20.5% had underlying medical conditions. In individuals aged 16 to 64, VE of primary vaccination within 90Â days was 35.6% (95% CI, 19.0â48.8%). After booster, VE increased to 68.7% (60.6â75.1%). In individuals aged â„65, VE of primary and booster was 31.2% (â44.0â67.1%) and 76.5% (46.7â89.7%), respectively. Relative VE of booster compared with primary vaccination was 52.9% (41.0â62.5%) in individuals aged 16 to 64 and 65.9% (35.7â81.9%) in individuals aged â„65. Conclusions During BA.1 and BA.2 epidemic in Japan, mRNA COVID-19 primary vaccination provided modest protection. Booster vaccination was necessary to protect against symptomatic infections
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
This study aimed to evaluate VE of primary, first, and second booster ancestral-strain monovalent mRNA COVID-19 vaccination against symptomatic infections and severe diseases in Japan. We conducted a test-negative case-control study. We included medically attended episodes and hospitalizations involving individuals aged â„16 with signs and symptoms from July to November 2022, when Omicron BA.5 was dominant nationwide. To evaluate VE, we calculated adjusted ORs of vaccination among test-positive versus test-negative individuals using a mixed-effects logistic regression. For VE against symptomatic infections among individuals aged 16 to 59, VE of primary vaccination atâ>â180âdays was 26.1% (95% CI: 10.6â38.8%); VE of the first booster was 58.5% (48.4â66.7%) at â€90âdays, decreasing to 41.1% (29.5â50.8%) at 91 to 180âdays. For individuals aged â„60, VE of the first booster was 42.8% (1.7â66.7%) at â€90âdays, dropping to 15.4% (â25.9â43.2%) at 91 to 180âdays, and then increasing to 44.0% (16.4â62.5%) after the second booster. For VE against severe diseases, VE of the first and second booster was 77.3% (61.2â86.7%) at â€90âdays and 55.9% (23.4â74.6%) afterward. mRNA booster vaccination provided moderate protection against symptomatic infections and high-level protection against severe diseases during the BA.5 epidemic in Japan.</p
Cherenkov Telescope Array Contributions to the 35th International Cosmic Ray Conference (ICRC2017)
List of contributions from the Cherenkov Telescope Array Consortium presented
at the 35th International Cosmic Ray Conference, July 12-20 2017, Busan, Korea.Comment: Index of Cherenkov Telescope Array conference proceedings at the
ICRC2017, Busan, Kore